Paul L. Berns, Director at Jazz Pharmaceuticals plc (JAZZ), sold 1,320 shares at $176.61 ($233K) on 2018-08-10, disclosed to the SEC on 2018-08-13.
Seasonal sale ($233k) by Director — this insider has traded JAZZ in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $176.61 | 660 | $117K | 50.0% |
| 2 | $176.61 | 660 | $117K | 50.0% |
| Total | $176.61 avg | 1,320 | $233K | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |